SH0 Stock Overview
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Shionogi & Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥46.60 |
52 Week High | JP¥48.60 |
52 Week Low | JP¥36.60 |
Beta | 0.36 |
1 Month Change | 6.39% |
3 Month Change | 9.91% |
1 Year Change | 10.95% |
3 Year Change | 1.75% |
5 Year Change | -13.54% |
Change since IPO | 241.64% |
Recent News & Updates
Recent updates
Shareholder Returns
SH0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -0.9% | 2.3% | 1.9% |
1Y | 11.0% | -25.9% | 7.3% |
Return vs Industry: SH0 exceeded the German Pharmaceuticals industry which returned -26.3% over the past year.
Return vs Market: SH0 exceeded the German Market which returned 6.4% over the past year.
Price Volatility
SH0 volatility | |
---|---|
SH0 Average Weekly Movement | 3.0% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SH0 has not had significant price volatility in the past 3 months.
Volatility Over Time: SH0's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1878 | 5,680 | Isao Teshirogi | https://www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
SH0 fundamental statistics | |
---|---|
Market cap | €13.44b |
Earnings (TTM) | €940.82m |
Revenue (TTM) | €2.59b |
14.3x
P/E Ratio5.2x
P/S RatioIs SH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SH0 income statement (TTM) | |
---|---|
Revenue | JP¥425.16b |
Cost of Revenue | JP¥60.08b |
Gross Profit | JP¥365.08b |
Other Expenses | JP¥210.62b |
Earnings | JP¥154.46b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
Earnings per share (EPS) | 542.78 |
Gross Margin | 85.87% |
Net Profit Margin | 36.33% |
Debt/Equity Ratio | 0% |
How did SH0 perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield28%
Payout RatioDoes SH0 pay a reliable dividends?
See SH0 dividend history and benchmarksShionogi dividend dates | |
---|---|
Ex Dividend Date | Mar 28 2024 |
Dividend Pay Date | Jun 24 2024 |
Days until Ex dividend | 1 day |
Days until Dividend pay date | 89 days |
Does SH0 pay a reliable dividends?
See SH0 dividend history and benchmarks